Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). 

Pharmaceutical

Karyopharm Therapeutics

Karyopharm Therapeutics' headquarters in Newton, MA, United States

Richard Paulson

Stephen Li

Emily Ziedman

Reshma Rangwala

Stuart Poulton

Mike Mano

Andrea Bottkova

Andrew Lancaster

Stephanie Quigley

Lisa A. Dipaolo

Lori Macomber

Lisa DiPaolo

Sohanya Cheng

Garen Bohlin

Chen Schor

Christy J. Oliger

Mansoor Raza Mirza

Deepa R. Pakianathan

Zhen Su

This department specializes in the diagnosis and treatment of blood and cancer-related disorders.

Hematology Oncology

The Leadership Team at Karyopharm Therapeutics is responsible for guiding the company's strategic direction and overall operations. Comprising executives from various disciplines, including research, commercial strategy, regulatory affairs, and investor relations, this team collaborates to drive innovation in drug development, ensure compliance with industry standards, and optimize business practices to successfully bring novel therapeutic solutions to market. Their collective expertise enables Karyopharm to effectively navigate challenges and capitalize on opportunities in the pharmaceutical landscape.

Leadership Team

The Research and Development team at Karyopharm Therapeutics focuses on advancing innovative drug candidates through comprehensive preclinical and clinical research. This multidisciplinary team collaborates on drug discovery, clinical strategy, regulatory affairs, and pharmacovigilance to ensure the safety and efficacy of novel therapies targeting cancer and other diseases. Their expertise spans various scientific and medical fields, driving the translation of groundbreaking research into potential treatment options.

Research and Development

The Clinical Operations team at Karyopharm Therapeutics is responsible for the planning, execution, and oversight of clinical trials to ensure the safe and efficient development of innovative therapies. This team collaborates closely with various stakeholders, manages clinical supply logistics, and ensures compliance with regulatory standards, all while driving the advancement of clinical programs that focus on the company's novel SINE compounds for cancer treatment.

Clinical Operations

This department oversees compliance and regulatory requirements in clinical operations and pharmacology.

Regulatory and Clinical Affairs

The Marketing and Communications team at Karyopharm Therapeutics is responsible for shaping and promoting the company's brand, engaging stakeholders, and communicating the value of its innovative therapies. This team collaborates across functions to develop strategic marketing initiatives, manage external partnerships, and facilitate comprehensive market access strategies that enhance the understanding and accessibility of Karyopharm's pioneering treatments for cancer and other serious conditions.

��

Karyopharm Therapeutics

Org chart

Board & advisors

Teams

Hematology Oncology

Leadership Team

Research and Development

Clinical Operations

Regulatory and Clinical Affairs

Marketing and Communications

Offices

��������

Karyopharm Therapeutics

Org chart

Board & advisors

Teams

Hematology Oncology

Leadership Team

Research and Development

Clinical Operations

Regulatory and Clinical Affairs

Marketing and Communications

Offices

Related companies

��